Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic Effects of Mitiperstat in HFpEF
NCT03611153Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing AZD4831 with Placebo (2 arms). Primary endpoints: Change in Exercise Pulmonary Capillary Wedge Pressure and Exercise Pulmonary Capillary Wedge Pressure. Started Jul 2018; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03611153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611153.